Modality
Gene Therapy
MOA
TROP-2 ADC
Target
PRMT5
Pathway
Tau
MDDOCD
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
Feb 2022
→ May 2031
Phase 3Current
NCT06400977
2,778 pts·OCD
2022-02→2031-05·Terminated
NCT03543410
1,365 pts·MDD
2023-12→2028-07·Terminated
4,143 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-07-022.3y awayPh3 Readout· MDD
2031-05-185.1y awayPh3 Readout· OCD
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2028-07-02 · 2.3y away
MDD
Ph3 Readout
2031-05-18 · 5.1y away
OCD
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06400977 | Phase 3 | OCD | Terminated | 2778 | SeizFreq |
| NCT03543410 | Phase 3 | MDD | Terminated | 1365 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 |